June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.
Author Affiliations & Notes
  • Rocio Blanco-Garavito
    Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Hassiba Oubraham
    Ophthalmology, Private Practice, Montargis, France
  • Benjamin Wolff
    Ophthalmology, Fondation Rothschild, Paris, France
  • Salomon Y Cohen
    Ophthalmology, Centre d'Imagerie et de Laser, Paris, France
  • Catherine P Garcher
    Ophthalmology, Centre Hospitalier Universitaire Dijon, Dijon, France
  • Jean-Francois Korobelnik
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
  • Christian Delhay
    Ophthalmology, Centre d'ophtalmologie du Mené-Ténénio, Vannes, France
  • Ramin Tadayoni
    Ophthalmology, Hopital Lariboisiere, Paris, France
  • Audrey Derveloy
    Ophthalmology Division, Novartis Pharma SAS, 2 Rue Lionel Terray, France
  • Eric H Souied
    Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Footnotes
    Commercial Relationships Rocio Blanco-Garavito, BAYER (R), Novartis Pharma SAS (C); Hassiba Oubraham, Allergan (C), Bayer (C), Novartis Pharma SAS (C); Benjamin Wolff, Novartis Pharma SAS (C); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis Pharma SAS (C), Thea (C); Catherine Garcher, Alcon (C), Allergan (C), Allumera (C), Basuch and Lomb (C), Bausch and Lomb (C), Bayer (C), Novartis Pharma SAS (C), Thea (C); Jean-Francois Korobelnik, Alcon (C), Alimera (C), Allergan (C), Bayer (C), Horus Pharma (C), Novartis Pharma SAS (C), Roche (C), Thea Pharmaceuticals (C); Christian Delhay, Allergan (C), Bayer (C), Novartis (C); Ramin Tadayoni, Alcon (C), Alimera (C), Allergan (C), Bausch and Lomb (C), Bayer (C), Dorc (C), Novartis Pharma SAS (C), Sony (C), Takeda (C), Thrombogenics (C), Zeiss (C); Audrey Derveloy, Novartis Pharma SAS (E); Eric Souied, Allergan (C), Bayer (C), Novartis Pharma SAS (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5364. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rocio Blanco-Garavito, Hassiba Oubraham, Benjamin Wolff, Salomon Y Cohen, Catherine P Garcher, Jean-Francois Korobelnik, Christian Delhay, Ramin Tadayoni, Audrey Derveloy, Eric H Souied, French LUMINOUS Group.; Baseline characteristics of French patients with wet age-related macular degeneration (wAMD) enrolled in the LUMINOUS study.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5364.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To describe the baseline characteristics of the French enrolled wAMD patients in the LUMINOUS (NCT01318941) study.

Methods: LUMINOUS is an ongoing, global, 5-year multicenter, prospective, observational study to evaluate the long-term safety, effectiveness, treatment patterns and health-related quality-of-life associated with ranibizumab (RBZ) treatment in clinical practice for all licensed indications. Interim data are available for a total of 17,545 adult wAMD patients globally. We analyzed the baseline characteristics of the 469 wAMD patients enrolled in France prior to March 2014.

Results: In the French wAMD cohort, 16 (3.4%) patients were treatment naïve (T1), 452 (96.4%) had received prior ranibizumab treatment (T2), and 1 (0.2%) had previously received other ocular treatments for wAMD. The baseline characteristics of the French/global wAMD cohorts were: mean age 79.0/77.4 years and 32.4/42.0% were male. For the French/global wAMD cohorts, mean baseline visual acuity (VA, Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) was 49.4/48.8 for T1 and 58.9/56.4 for T2; 68.9/42.4% had Pigment Epithelium Detachment (PED). Non-ocular comorbidities for the French/global wAMD patients included myocardial infarction (5.5/7.3%), stroke (5.5/5.6%), other thromboembolic events (4.9/4.9%), family history of coronary artery disease (14.1/14.9%), diabetes (10.7/14.5%), hypertension (51.4/56.7%), and obesity (BMI >30kg/m2; 11.5/10.0%). For those having received prior ranibizumab treatment, the mean duration of treatment was 2.5 years and the mean number of injections/year was 5.6.

Conclusions: The French wAMD patients enrolled in the LUMINOUS study were slightly older, had similar baseline VA, a greater proportion had PED, and a similar proportion had non-ocular comorbidities at baseline, compared to the global cohort. In both cohorts, prior ranibizumab treated patients had higher VA at baseline than treatment naïve patients. Future follow-up data from this cohort of French patients will provide an invaluable source of information from a diverse group of patients currently underrepresented in randomized clinical trials.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.